Bosh sahifaBH3 • FRA
add
PTC Therapeutics, Inc.
Yopilish kursi
59,28 €
Kunlik diapazon
58,08 € - 58,08 €
Yillik diapazon
32,00 € - 75,00 €
Bozor kapitalizatsiyasi
5,66 mlrd USD
Narx/foyda
-
Dividend daromadliligi
-
Asosiy maydon
NASDAQ
Yangiliklarda
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (USD) | dek, 2025info | Y/Y qiyosi |
|---|---|---|
Daromad | 164,68 mln | -22,75% |
Joriy xarajat | 106,22 mln | 20,72% |
Sof foyda | -134,96 mln | -104,85% |
Sof foyda marjasi | -81,96 | -165,16% |
Har bir ulushga tushum | -1,80 | -425,82% |
EBITDA | -68,72 mln | -654,61% |
Amaldagi soliq stavkasi | 2,96% | — |
Balans
Jami aktivlari
Jami passivlari
| (USD) | dek, 2025info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 1,95 mlrd | 68,66% |
Jami aktivlari | 2,90 mlrd | 70,01% |
Jami passivlari | 3,10 mlrd | 10,74% |
Umumiy kapital | -205,31 mln | — |
Tarqatilgan aksiyalar | 82,77 mln | — |
Narxi/balansdagi bahosi | -23,52 | — |
Aktivlardan daromad | -7,36% | — |
Kapitaldan daromad | -8,44% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (USD) | dek, 2025info | Y/Y qiyosi |
|---|---|---|
Sof foyda | -134,96 mln | -104,85% |
Operatsiyalardan naqd pul | -34,27 mln | -14,23% |
Sarmoyadan naqd pul | 34,01 mln | -87,30% |
Moliyadan naqd pul | 302,50 mln | 1 042,78% |
Naqd pulning sof oʻzgarishi | 312,03 mln | 22,11% |
Boʻsh pul | -42,01 mln | -11 770,05% |
Haqida
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control mechanisms in orphan diseases.
In September 2009, PTC entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system diseases. PTC acquired the Bio-e platform in 2019. Wikipedia
Tashkil etilgan
1-yan, 1998
Sayt
Xodimlar soni
991
